246

10. Arias TD, Jorge LF, Inaba T. No evidence for the

present of poor metabolizers of sparteine in an

Amerindian group. Br J Clin Pharmac, 21, 547-549,

1986.

11. Arunkumar Shastri R. Undernourrished adults and

acetylation phenotype. Int J Clin Pharmacol Ther

Toxicol. 20r 194-196, 1982.

12. Arvela P, Kirjarinta M, Krki N, Pelkonen O.

Polymorphism of debrisoquine hydroxylation among Finns

and Lapps. Br J Clin Pharmacol, 26, 601-603, 1988.

13. Azad Khan AK, Nurazzaman M, Truelove SC. The effect of

the acetylator phenotype on the metabolism of

suphasalazine in man. J Med Genetics. 20, 30-36,

1983.

14. Balant-Gorgia AE, Schulz P, Dayer P, Balant L, Kubli

A, Gertsch C, Garrone G. Role of oxidation

polymorphism on blood and urine concentrations of

247

amitriptyline and its metabolites in man. Arch

Psvchiat Neurol Sci. 232. 215-222, 1982.

15. Bamrah JS, Soni SD. Drug-induced Parkinson's disease.

Lancet. 1, 1031-1032, 1987.

16. Barbeau A, Cloutier T, Roy M, Plasse L, Paris S,

Poirier J. Ecogenetics of Parkinson's disease:

4-hydroxylation of debrisoquine. Lancet, 2.,

1213-1216, 1985.

17. Barclay WR, Ebert RH, Le Roy GV, Manthei RW, Roth LJ.

Distribution and excretion of radioactive isoniazid in

tuberculous patients. JAMA. 151. 1384-1388, 1953.

18. Batchelor JR, Welsh KI, Mansilla-Tinoco R, Collery CT,

Hughes GRV, Bernstein R, Ryan P, Naish PF, Abler GM,

Bing RF, Russell GI. Hydralazine-induced systemic lupus

erythematosus: Influence of HLA-DR and sex on

susceptibility.. Lancet, 1, 1107-1109, 1980.

248

19. Benítez J, Llerena A, Cobaleda J. Debrisoquin

oxidation polymorphism in a Spanish population. Clin

Pharmacol Therf 44f 74-77, 1988.

20. Bertilsson L, Aberg-Wistedt A. The debrisoquine

hydroxylation test predicts steady-state plasma levels

of desipramine. Br J Clin Pharmacol, 15, 388-390,

1983.

21. Bertilsson L, Dengler HJ, Eichelbaum M, Schultz HU.

Pharmacogenetic covariation of defective N-oxidation

of sparteine and 4-hydroxylation of debrisoquine. Eur

J Clin Pharmacol. 17. 153-155, 1980.

22. Bertilsson L, Eichelbaum M, Mellstrom B, Sawe J,

Schultz HU, Sjqvist F. Nortriptyline and antipyrine

clearance in relation to debrisoquine hydroxylation

in man. Life Sci. 27. 1673-1677, 1980.

23. Bienzle U. Glucose-6-phosphate dehydrogenase

deficiency. Part I: Tropical Africa. Clin Haematolf

10, 785-799, 1981.

249

24. Blain PG, Mucklow JC, Wood P, Roberts DF, Rawlins MD.

Family study of antipyrine clearance. Br Med J,

284, 150-152, 1982.

25. Bloom, GE, Zarkowsky HS. Heterogeneity of the

enzymatic defect in congenital methemoglobinemia.

N Enql J Med. 281. 919, 1969.

26. Bodansky HJ, Drury PL, Cudworth AG, Price Evans DA.

Acetylator phenotypes and type I (insulin-dependent)

diabetics with microvascular disease. Diabetes.

10, 907-910, 1981.

27. Boobis AR, Murray S, Khan GC, Robertz G-M, Davies DS.

Substrate specificity of the form of cytochrome P-450

catalyzing the 4-hydroxylation of debrisoquine in man.

Mol Pharmacol. 23. 471-481, 1983.

28. Breimer DD. Interindividual variations in drug

disposition: clinical implications and methods of

investigation. Clin Pharmacokin. 8., 371-377, 1983.

250

29. Brosen K, Otton SV, Gram LF. Spartein oxidation

polymorphism in Denmark. Acta Pharmacol Toxicol. 57,

357-360, 1985.

30. Brosen K, Gram LF. Clinical significance of the sparteine/

debrisoquine oxydation polymorphism. Eur J Clin Pharmacol,

16, 537-547, 1989.

31. Bulovskaya LN, Krupkin RG, Bochina TA, Shipkova AA,

Pavlova MV. Acetylator phenotype in patients with

breast cancer. Oncologyf 35, 185-188, 1978.

32. Burns RS, Markey SP, Philips JM, Chilich CC. The

neurotoxicity of l-methyl-4-phenyl-l-l,2,3,6-

-tetrahydropyridine in the monkey and man. Can J

Neurol Sci. 11 fsuppl). 166-169, 1984.

33. Burrows AW, Hockaday TDR, Mann JI, Taylor JG. Diabetic

dimorphism according to acetylator status. Br Med J.

1, 208-210, 1978.

251

34. Calne DB, Bisen A, McGeer E, Spencer P. Alzheimer's

disease, Parkinson's disease, and motoneurone disease:

abiotropic interaction between ageing and

environment?. Lancet. 2, 1067-1070, 1986.

35. Calne DB, Langston JW. Aetiology of Parkinson's

disease. Lancet. 2, 1457-1459, 1983.

36. Cartwright RA, Glashen RW, Rogers HJ, Ahmad RA,

Barham-Hall D, Higgins E, Kahn MA. Role of

N-acetyltransferase phenotypes in bladder

carcinogenesis: a pharmacogenetic epidemiological

approach to bladder cancer. Lancet, 2., 842-845,

1982.

37. Chapman CJ. Drugs and genes: therapeutic implications,

Drugs. 14, 120-127, 1977.

38. Champman LJ, Peters HA, Matthews CG, Levine RL.

Parkinsonism and industrial chemicals. Lancet, JL,

332-333, 1987.

252

I .

39. Chapron DJ, Blum MR. Relationship of sulphamethazine

disposition kinetics to acetylator phenotype in man.

J Clin Pharmacol. 16, 338-344, 1976.

40. Chapron DJ, Kramer PA, Mercik SA. Potential influence

of body weight on the clearance of polymorphically

acetylated drugs. J Clin Pharmacol. 22, 271-275,

1982.

41. Clark DWJ. Simultaneous phenotyping for oxidation and

acetylation status. Proceedings of the University of

Otago Medical School Dunedin NZ. 61, 30-32, 1983.

42. Clark DWJ, Blain PG, Rawlins MD, Roberts DH.

Pharmacogenetic screening in the general population.

(Abstract). Clin Exp Pharmacol Phvsiolf Suppl 8,

67, 1984.

43. Clark DWJ, Morgan A, Waal-Manning H. Adverse effects

from metoprolol are not generally associated with

oxidation status. Br J Clin Pharmacol. 18, 965-967, 1985,

253

44. Clark DWJ. Genetically determined variability in

acetylation and oxidation. Therapeutic implications.

Drugs. 29, 342-375, 1985.

45. Clark DWJ, Edwards IR. Adverse drug reaction reporting

and retrospective phenotyping for oxidation

polymorphism. Med Toxicol. 3., 241-247, 1988.

46. Cohen RJ, Sachs JR, Wicker DJ, Conrad ME.

Methemoglobinemia provoked by malarial

chemoprophylaxis in Vietnam. N Engl J Medf 279,

1127-1131, 1968.

47. Coombes RC, Foster AB, Harland SJ, Jarman M, Nice EC.

Polymorphically acetylated aminoglutethimide in

humans. Br J Cancer, 46P 340-345, 1982.

48. Cooper RG, Price Evans DA, Whibley EJ. Polymorphic

hydroxylation of perhexiline maléate in man. J Med

Genetics, .21, 27-33, 1984.

254

49. Cowan GO, Das KM, Eastwood MA. Further studies of

sulphasalazine metabolism in the treatment of

ulcerative colitis. Br Med J. 2, 1057-1059, 1977.

50. Danhof M, de Groot-van der Vis E, Breimer DD. Assay of

antipyrine and its primary metabolites in plasma,

saliva and urine by high-performance liquid

chroraatography with some preliminary results in man.

Pharmacology, 18. 210-223, 1979.

51. Danhof M, Idle JR, Teunissen NWE, Sloan TP, Breimer

DD, Smith RL. Influence of the genetically controlled

deficiency in debrisoquine hydroxylation on antipyrine

metabolite formation. Pharmacology, 22, 349-358,

1981.

52. Davidson J, Me Leod NN, Blum MR. Acetylation phenotype,

platelet raonoamine oxydase inhibition, and the

effectiveness of phenelzine in depression. Am J Psychiat,

135f 467-469, 1978.

255

53. Davies DS, Beedie MA, Rawlins MD. Antinuclear

antibodies during procainamide treatment and drug

acetylation. Br Med J, 3., 682-683, 1975.

54. Davies DS, Boobis AR. Variants of human microsomal

enzymes. Biochem Soc Transactions, II, 459-460,

1983.

55. Davis GC, Williams AC, Markey SP, et al. Chronic

parkisonism secondary to intravenous injection of

meperidine analogues. Psychiat Res. I, 249-254,

1979.

56. Dayer P, Balant L, Kupfer A, Courvoisier F, Fabre J.

Contribution of the genetic status of oxidative

metabolism to variability in the plasma concentrations

of beta-adrenoceptor blocking agents. Eur J Clin

Pharmacol. 24., 797-799, 1983.

j 57. Dayer P, Courvoisier F, Balant L, Fabre J.II Beta-blockers and drug oxidation status. Lancetfí

1, 509, 1982.

256

58. Dayer P, Leemannt T, Marmy A, Rosenthaler J.

Interindividual variation of beta-adrenoreceptor

blocking drugs, plasma concentration and effect:

influence of genetic status on behaviour of atenolol,

bopindol and metoprolol. Eur J Clin Pharmacolf 28.

149-153, 1985.

59. De Lúea HF, Suttie JW (eds). The Fat soluble vitamins,

University of Wisconsin Press. Madison, 1970.

60. De Matteis F. Disturbances of liver porphyrin

metabolism caused by drugs. Pharmacol Revf 19.

523-557, 1967.

61. de Wolff FA, Vermeij P, Ferrari MD, Buruma OJS,

Breimer DD. Impairment of phenytoin parahydroxylation

as a cause of severe intoxication. Ther Drug Monit,

5, 213-215, 1983.

62. Devadatta S, Gangadharan PRJ, Andrews RH, Fox W,

Ramakrishnan CV, Shelon JB, Veru S. Peripheral

neuritis due to isoniazid. Bull World Health

257

Organization, 23, 587-598, 1960.

63. Dickinson DS, Bailey WC, Hirschowitz DI, Soong SJ,

Eidus L, Hodking MM. Risk factors for isoniazid

(INH)-induced liver dysfunction. J Clin

Gastroenterol. 3., 271-279, 1981.

64. Drayer DE, Reidenberg MM. Clinical consequences of

polymorphic acetylation of basic drugs. Clin

Pharmacol Ther. 22. 251-258, 1977.

65. Drayer DE, Reidenberg MM, Sevy RW.

N-acetylprocainamide: an active metabolite of

procainamide. Proc Soc Exp Biol Med, 146. 358-363,

1974.

66. Drayer P, Leeman T, Striberni R. Dextrometorphan

0-demethylation in liver microsomes as a prototype

to monitor cytocrome P450 dbl activity. Clin Pharmacol

:, 45. 34-40, 1989.

67. du Souich P, Lalka D, Slaughter R, Elvin AT, McLean

258

AJ. Mechanisms of non-linear disposition kinetics of

sulphamethazine. Clin Pharmacol Ther, 25, 172-183, 1979

68. du Souich P, McLean AJ, Stoeckel K, Ohlendorf D,

Gibaldi M. Screening methods using suphamethazine for

determining acetylator phenotype. Clin Pharmacol

Ther, 26. 757-765, 1979.

69. Ehrenfeld N, Zylber-Katz E, Levy M. Acetylator

phenotype in rheumatoid arthritis. Israel J Med Sci,

19. 368-379, 1983.

70. Eichelbaum M. Defective oxidation of drugs:

pharmacokinetic and therapeutic implications. Clin

Pharmacokin, 7_, 1-22, 1982.

71. Eichelbaum M, Bertilsson L, Sawe J. Antipyrine

metabolism in relation to polymorphic oxidations of

sparteine and debrisoquine. Br J Clin Pharmacol,

15, 317-321, 1983.

\

259

72. Eichelbaum M, Bertilsson L, Sawe J, Zekorn C.

Polymorphic oxidation of sparteine and debrisoquine:

related pharmacogenetic entities. Clin Pharmacol

Ther. 31, 184-186, 1982.

73. Eichelbaum M, Spannbrucker N, Steincke B, Dengler HJ.

Defective N-oxidation of sparteine in man: a new

pharmacogenetic defect. Eur J Clin Pharmacolf 16.

183-187, 1979.

74. Eichelbaum M, Woolhouse NM. Inter-ethnic differences in

sparteine oxydation among Ghanaians and Germans. Eur

Clin Pharmacol, 28. 79-83, 1985.

75. Eidus L, Harnanansingh HM, Jessamine AG. Urine test

for phenotyping isoniazid inactivators. Am Rev Respir

Pis. 104. 587, 1971.

76. Eidus L, Ling GM, Harnanansingh AMT. Isoniazid

excretion in fast and slow inactivators and its

practical aspect for phenotyping. Arzneimittel-

Forschuna. 21. 1696-1699, 1971.

269

77. Ellard GA. Variations between individuals and

populations in the acetylation of isoniazid and its

significance for the treatment of pylmonary tuberculosis,

Clin Pharmacol Ther. 19. 610-625, 1976.

78. Ellard GA, Gammon PT. Acetylator phenotyping of

tuberculosis patients using matrix isoniazid or

sulphadimidine and its prognostic significance for

treatment. Br J Clin Pharmacolf 4_, 5-14, 1977.

79. Elson J, Strong JM, Atkinson Jr AJ. Antiarrythmic

potency of N-acetylprocainamide. Clin Pharmacol

Ther. 17. 134-140, 1975.

80. Erdtmansky P, Goelh TJ. Gas-liquid chromatographic

electron capture determination of some monosubstituted

guanido-containing drugs. Analytical Chemistryf

47. 750-752, 1975.

81. Farah F, Taylor W, Rawlins MD, James O. Hepatic drug

acetylation and oxidation: effects of ageing in man.

Br Med J. 2, 155-156, 1977.

261

82. Fine A, Summer DJ. Determination of acetylator status

in uraemia. Br J Clin Pharmacolf 2, 475-476, 1975.

83. Fishbein E, Alarcon-Segovia D. Slow acetylation

phenotype in systemic lupus erythematosus. Arthr

Rheumat f 22. 95-96, 1979.

84. Foad B, Litwin A, Zimmer H, Hess EV. Acetylator

phenotype in systemic lupus erythematosus. Arthr

Rheumat f 20. 815-818, 1977.

85. Gachályi B, Vas À, Hajós P, Káldor A. Acetylator

phenotypes: effect of age. Eur J Clin Pharmacol,

26, 43-45, 1984.

86. Gelber R, Peters JH, Gordon GR, Glazko AJ, Levy L. The

polymorphic acetylation of dapsone in man. Clin

Pharmacol Therf 12, 225-238, 1971.

87. Girling DJ. The hepatic toxicity of antitubercular

regimes containing isoniazid, rifampicin and

pyrazinamide. Tubercle. 59, 13-32, 1978.

IIí/fi

262

88. Glowinski IB, Radtke HE, Weber WW. Genetic variation

in N-acetylation of carcinogenic arylamines by human

and rabbit liver. Molec Pharmacol. 14. 940-949,

1978.

89. Goldstein PD, Alpers DH, Keating JT. Sulphapyridine

metabolites in children with inflammatory bowel

disease receiving sulphasalazine. J Pediatr. 95,

638-640, 1979.

90. Graham JB, Falls VWMC, Winters RW. Familial

hypophosphatemia with vitamin D resitant rickets. II.

Three additional kindreds of the sex-linked dominant

type with a genetic analysis of four such families.

Amer J Human Genet. 11. 311, 1959.

91. Grant DM, Tang BK, Kalow W. Polymorphic N-acetylation

of a caffeine metabolite. Clin Pharmacol Ther, 33,

355-359, 1983.

92. Grant DM, Tang BK, Kalow W. Variability in caffeine

263

metabolism. Clin Pharmacol Therf 33, 591-602,

1983.

93. Grant DM, Tang BK, Kalow W. A simple test for

acetylator phenotype using caffeine. Br J Clin

Pharmacol. 17, 459-464, 1984.

94. Gronhagen-Riska C, Heistrom PE, Froseth B.

Predisposing factors in hepatitis induced by

isoniazid-rifampicin treatment of tuberculosis. Am

Rev Respir Pis. 118. 461-466, 1978.

95. Hall S. Evaluation of the sulphadimidine acetylator

phenotyping test in a patient with reduced renal

function. Acta Med Scand. 209, 505-507, 1981.

96. Hanson A, Mclander A, Wahlin , Boll E. Acetylator

phenotyping: a comparison of the isoniazid and dapsone

tests. Eur J Clin Pharmacol. 20f 233-234, 1981.

97. Harland SJ, Facchini V, Timbrell JA. Hydralazine-

.e*>;

264

induced lupus erythematosus-1ike syndrome

in a patient of the rapid acetylator phenotype. Br

Med J. 281. 273-274, 1980.

98. Harris JW. The Red Cell. Harvard University Press.

Cambridge, 1970.

99. Harris H, Hopkinson DA, Luffman J. Enzyme diversity

in human populations. Ann N Y Acad Scif 151. 232-242,

1968.

100. Horai Y, Ishizaki T. Pharmacogenetics and its

clinical implications: N-acetylation polymorphism.

Rational Drug Therapy. 21. 10-17, 1987.

101. Horai Y, Ishizaki T, Sasaki T, Koya G, Matsuyama K,

Iguchi S. Isoniazid disposition, comparison of

isoniazid phenotyping methods in and acetylator

distribution of Japanese patients with idiopathic

sistemic lupus erytheraatosus and control subjects. Br

J Clin Pharmacol. 13., 361-374, 1982.

265

102. Horai Y, Ishizaki T. N-acetylation polymorphism of

dapsone in a Japanese population. Br J Clin

Pharmacol. 25, 487-494, 1988.

103. Horai Y, Zhou H, Zhang L, Ishizaki T. N-acetylation

phenotyping with dapsone in a mainland Chinese

population. Br J Clin Pharmacol, 25, 81-87, 1988.

104. Horai Y, Ishizaki T. Pharmacogenetics and its

clinical implications .Partll. Oxidation polynorphism.

Rational Drug Therf 22. 6-1, 1988.

105. Hunyor SN. Hydralazine and beta-blockade in

refractory hypertension with characterization of the

acetylator phenotype. Austr N Z J Med, 5_, 530-536,

1975.

106. Hutchinson D, Wyld PJ. Sulphasalazine-induced

agranulocytosis. N Z Med J, 96. 520-521,

1983.

266

107. Idle JR, Mahgoub A, Lancaster R, Smith RL.

Hypotensive response to debrisoquine and

hydroxylation phenotype. Life Sci. 22, 979-984,

1978.

108. Idle JR, Smith RL. Polimorphism of oxidation at

carbon centers of drugs and their clinical

significance. Drug Metab Rev, 9_, 301-317, 1979.

109. Idle JR, Mahgoub A, Sloan TP, Smith RL, Mbanefo CO,

Bababunmi EA. Some observations on the oxidation

phenotype status of Nigerian patients presenting with

cancer. Cancer Letters, 11, 311-338, 1981.

110. Idle JR, Gates NS, Shah RR, Smith RL. Is there a

genetic predisposition to phenphormin-induced lactic

acidosis? Br J Clin Pharmacol. 11, 418P-419P,

1981.

111. Idle JR, Dates NS, Shah RR, Smith RL. Protecting poor

metabolisers: a group at risk of adverse reactions.

Lancet. 1, 1388, 1983.

267

112. Idle JR, Ritchie JC, Smith RL. Oxidation phenotype

and metiamide metabolism. Br J Pharmacol, 66,

432P, 1979.

113. Idle JR, Sloan TP, Smith RL, Wakile LA. Application

of the phenotyped panel approach to the detection of

polymorphism of drug oxidation in man. Br J

Pharmacol. 66. 430P-431P, 1980.

114. Inaba T, Otton SV, Kalow W. Deficient metabolism of

debrisoquine and sparteine. Clin Pharmacol Ther.

27., 547-549, 1980.

115. Inaba T, Otton SV, Kalow W. Debrisoquine

hydroxylation capacity: problems of assessment in

two populations. Clin Pharmacol Therf 29,

218-223, 1981.

116. Inaba T, Vinks A, Otton SW, Kalow W. Comparative

pharmacogenetics of sparteine and debrisoquine. Clin

Pharmacol Ther. 3_3., 394-399, 1983.

268

117. Inaba T, Jurima M, Nakano M, Kalow W. Mephenytoin and

sparteine pharmacogenetics in Canadian Caucasians.

Clin Pharmacol Ther. 36. 670-676, 1984.

118. Inaba T, Jorge LF, Arias TD. Mephenytoin

hydroxylation in the Cuna amerindians of Panama. Br

J Clin Pharmacol. 25. 75-79, 1988.

119. Ishizaki T, Horai Y, Koya G, Matsuyama K, Iguchi S.

Acetylator phenotype and metabolic disposition of

isoniazid in Japanese patients with systemic lupus

erythematosus. Arthr Rheumatf Z.4 r 1245-1254,

1981.

120. Islam SI, Idle JR, Smith RL. The polymorphic

4-hydroxylation of debrisoquine in a Saudi Arab

population. Xenobiotica. 10f 819-825, 1980.

121. Jack DB, Kendall MJ. Beta-blockers and debrisoquine

metaboliser status. Lancet, JL, 741, 1982.

269

122. Jack DB, Wilkins N, Quarterman CP. Lack of evidence

for polymorphism in metoprolol metabolism. Br J Clin

Pharmacol. 16. 188-190, 1983.

123. Johansson E, Mustakallio KK, Mattila MJ. Polymorphic

acetylator phenotype and systemic lupus erythematosus,

Acta Med Scand. 210. 193-196, 1981.

124. Johnstone EC, Marsh W. The relationship between

response to phenelzine and acetylator status in

depressed patients. Proc Royal Soc Medf 66f

947-949, 1973.

125. Jounela AJ, Pasanen M, Matilla MJ. Acetylator

phenotype and the antihypertensive response to

hydralazine. Acta Med Scand. 197f 303-306, 1975.

126. Jurima M, Inaba T, Kalow W. Sparteine oxidation by

the human liver. Absence of inhibition by

mephenytoin. Clin Pharmacol Ther, 35, 426-428,

1984.

270

127. Kahn GC, Boobis AR, Murray S, Brodie MJ, Davies DS.

Assay and characterisation of debrisoquine

4-hydroxylase activity of microsomal fractions of

human liver. Br J Clin Phariaacol. 13, 637-645,

1982.

128. Kalow W. Pharmacoqenetics; heredity and the response

to drugs. WB Saunders. Philadelphia, 1962.

129. Kalow W. Topics in pharmacogenetics. Ann NY Acad Sci,

179. 654-659, 1971.

130. Kalow W. Ethnic differences in drug metabolism. Clin

Pharmacokin, 7., 373-400, 1982.

131. Kappas A, Bradlow HL, Gilette PN, Levere RD,

Gallagher TF. A defect of steroid hormone metabolism

in acute intermittent porphyria. Fed Proc. 31f 1293,

1972.

132. Karim AKMB, Price Evans DA. Polymorphic acetylation

of nitrazepam. J Med Genet, 13. 17-19, 1976.

271

133. Kellerman G, Kellerman ML, Horning MG, Stafford M.

Elimination of antipyrine and benzo(a)pyrene

metabolism in cultured human lymphocytes. Clin

Pharmacol Ther. 20. 72-80, 1976.

134. Kirkraan HN. Glucose-6-phosphate dehydrogenase

variants and drug-induced hemolysis. Ann NY Acad

Sci. 151. 753, 1968.

135. Kitchin I, Tremblay J, Andre J, Dring LG, Idle JR,

Smith RL, Williams RT. Individual and interspecies

interaction in the metabolism of the hallucinogen

4-methoxyamphetamine. Xenobioticaf 9_, 397-404,

1979.

136. Kleinbloesen CH, Van Brummelen P, Faber H, Danhof M,

Vermeulen NPE, Breimer DD. Variability in nifedipine

pharmacokinetics and dynamics: a new oxydation

polymorphism in man. Biochem Pharmacolf 33.

3721-3724, 1984.

272

137. Kroemer HK, Mikus G, Kronbach T, Meyer VA, Eichelbaum M.

In vitro characterization of the human cytocrome P450

involved in polymorphic oxidation of propafenone. Clin

Pharmacol Ther. 45. 28-33, 1989.

138. Kong I, Devonshire HW, Cooper M, Sloan TP, Idle JR,

Smith RL. The influence of oxidation phenotype on

phenacetin metabolism and haemotoxicity. Br J Clin

Pharmacol. 13. 275P-276P, 1982.

139. Kupfer A, Dick B, Preisig R. Polymorphic mephenytoin

hydroxylation in man: a new phenotype in the genetic

control of hepatic drug metabolism. Hepatolocfv.

81, 34, 1981.

140. Kupfer A, Schmid B, Preisig R, Pfaff G.

Dextromethorphan as a safe probe for debrisoquine

hydroxylation polymorphism. Lancet, 2., 517-518,

1984.

141. Kutt H. Biochemical and genetic factors regulating

273

Dilantin metabolism in man. Ann NY Acad Scif

179. 704-722, 1971.

142. Kutt H, Brennan R, Dehejia H, Verebely K.

Diphenylhydantoin intoxication. A complication of

isoniazid therapy. Am Rev Respir Disf 101, 377-384,

1970.

143. Kutt H, Wolk M, Scherman R, McDowell F. Insufficient

co-hydroxylation as a cause of diphenylhydantoin

toxicity. Neurology. 14, 542-548, 1964.

144. Ladero JM, Arroyo A. Envejecimiento y fenotipo

acetilador hepático. Rev Iberoamer Invest Clin.

2, 21-26, 1983.

145. Ladero JM, Arrojo A, de Salamanca RE, Gomez M, Cano

F, Alfonso M. Hepatic acetylator phenotype in

diabetes mellitus. Ann Clin Res. 14, 187-189,

1982.

274

146. Ladero JM, Arrojo A, Gilsanz V. Acetilación hepática

en la población española. Gastroenterol Hepatol.

2., 236-240, 1979.

147. Ladero JM, Fernández MJ, Jiménez LC. Influencia del

sexo, la edad y la pigmentación corporal sobre el

polimorfismo acetilador. An Med Intern

(Madrid). 5, 241-244, 1988.

148. Ladero JM, Fernández HJ, Palmeiro R, Muñoz JJ, Jara C,

Lázaro C, Pérez-Manga G. Hepatic acetylator polymorphism

in breast cancer patients. Oncology, 44. 341-344, 1987.

149. Lahita R, Kluger J, Drayer DE, Koffler D, Reidenberg

MM. Antibodies to nuclear antigens in patients

treated with procainamide or acetylprocainamide.

N Encfl J Med. 301. 1382-1385, 1979.

150. Langston JW, Forno LS, Rebert CS, Irwin I. Selective

nigral toxicity after systemic administration of

l-methyl-4-phenyl-l,2,5,6-tetrahydropyridine (MPTP).

Brain Res. 292. 390-394, 1984.

275

151. Langston JW, Ballard P. Parkinsonism induced by

l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine (MPTP):

implications for treatment and the pathogenesis of

Parkinson's disease. Can J Neurol Scif 11 (suppl),

160-165, 1984.

152. Langston JW. Closer to Parkinson's disease: MPTP and

the aging nervous system. Trends Pharmacol Scif

81, 7-8, 1987.

153. Larsson R, Karlberg BE, Norlander B, Wirsen A.

Prizidilol, an antihypertensive with precapillary

vasodilator and beta-adrenoceptor blocking actions in

primary hypertension. Clin Pharmacol Ther, 29,

588-593, 1981.

154. Larsson R, Karlsson E, Molin L. Spontaneous systemic

lupus erythematosus and acetylator phenotype. Acta

Med Scand. 201. 223-226, 1977.

155. Lawson DH, Henry DA, Lowe J, Reavey P, Rennie JA,

276

Solomon A. Acetylator phenotype in spontaneous SLE

and rheumatoid arthritis. Ann Rheum Pis, 38.

171-173, 1979.

156. Leclercq V, Desager JP, van Nienwenhuyze Y, Harvengt

C. Prevalence of drug hydroxylator phenotypes in

Belgium. Eur J Clin Pharmacol, 33, 439-440, 1987.

157. Lee EJ, Lee LKH. A simple pharmacokinetic method for

separating the three acetylation phenotypes: a

preliminary report. Br J Clin Pharmacolf 13.

375-378, 1982.

158. Leden I, Hanson A, Melander A, Sturfelt G, Svensson

B, Wahlin-Boll E. Varying distribution of acetylation

phenotypes in RA patients with and without Sjogren's

syndrome. Scand J Rheumf 10, 253-255, 1981.

159. Lennard MS, Freestone S, Ramsay LE, Tucker GT, Woods

HF. Oxidation phenotype and beta-blockers. N Engl J

Med. 308. 965, 1983.

277

160. Lennard MS, Silas JH, Smith AJ, Tucker GT.

Determination of debrisoquine and its 4-hydroxy

metabolite in biological fluids by gas chromatography

with flame-ionisation and nitrogen-selective detection.

J Chromatr 133. 161-166, 1977.

161. Lennard MS, Silas JH, Freestone S, Ramsay LE, Tucker

GT, Wood HF. Oxydation phenotype - a major

determinant of metoprolol metabolism and response.

N Encrl J Med. 303. 1558-1560, 1982.

162. Lennard MS, Silas JH, Freestone S, Trevethick J.

Defective metabolism of metoprolol in poor

hydroxylators of debrisoquine. Br J Clin Pharmacol.

14, 301-303, 1982.

163. Lennard MS, Jackson PR, Freestone S, Tucker GT,

Ramsay LE, Woods HF. The relationship between

debrisoquine oxidation phenotype and the

pharmacokinetics and pharmacodynamics of propranolol.

Br J Clin Pharmacol. 17. 679-685, 1984.

278

164. Lennard MS, Tucker GT, Silas MD, Freestone S, Ramsay

LE, Woods HF. Differential stereoselective metabolism

of metoprolol in extensive and poor debrisoquine

metabolizers. Clin Pharmacol Ther. 34. 732-737,

1983.

165. Lennard MS, Tucker GT, Woods HF. The polymorphic

oxidation of /3-adrenoceptor antagonists. Clinical

pharmacokinetic considerations. Clin Pharmacokin,

11. 1-17, 1986.

166. Lennard MS, Tuccker GT, Woods HF, Silas JH, lyun ÀO.

Stereoselective metabolism of metoprolol-relationship

to debrisoquine oxydation phenotype. Br J Clin Pharmacol,

17, 1989.

167. Lima JJ, Conti DR, Goldfarb AL, Tilstone WJ, Golden

LH, Jusko WJ. Clinical pharmacokinetics of

procainamide infusions in relation to acetylator

phenotype. J Pharmacokin Biopharm, 7_, 69-85, 1979.

279

168. Lou Y-Ch, Ying L, Bertilsson L, Sjqvist F. Low

frequency of slow debrisoquine hydroxylation in a

Chinese population. Lancet, 2., 852-853, 1987.

169. Lower Jr GM, Nilsson T, Nelson CE, Wolf H, Gamsky TE,

Bryan GT. N-acetyltransferase phenotype and risk in

urinary bladder cancer. Approaches in molecular

epidemiology. Environm Health Perspect. 29,

71-79, 1979.

170. Lunde PKM, Frislid K, Hansteen V. Disease and

acetylation polymorphism. Clin Pharmacokin. 2.,

182-197, 1977.

171. Macklon AF, Savage RL, Rawlins MD. Gilbert's syndrome

and drug metabolism. Clin Pharmacokin, 4., 223-232,

1979.

172. Mahgoub A, Idle JR, Dring LG, Lancaster R, Smith RL.

Polymorphic hydroxylation of debrisoquine in man.

Lancet. 2., 584-586, 1977.

280

173. Mahgoub A, Idle JR, Smith RL. A population and

familial study of the defective salicylic

hydroxylation of debrisoquine among Egyptians.

Xenobiotica. 9., 51-56, 1979.

174. Mansilla-Tinoco R, Harland SJ, Ryan PJ, Berstein RM,

Dollery CT, Hughes GRV, Bulpitt CJ, Morgan A, Jones

JM. Br Med J. 284. 936-939, 1982.

175. March P. Metabolismo de la isoniazida. Tesis

doctoral. Barcelona, 1966.

176. Marsden CD. Neurotransmitters and CNS disease. Basal

ganglia disease. Lancet, 2, 1141-1147, 1982.

•i-111. Marshall EF, Mountjoy CQ, Campbell 1C, Garside RF,

Leitch IM, Roth M. The influence of acetylator

phenotype on the outcome of treatment with

phenelzine, in a clinical trial. Br J Clin

Pharmacol. 6, 247-254, 1978.